Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 24,000 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $26.00, for a total transaction of $624,000.00. Following the sale, the vice president now owns 24,000 shares of the company’s stock, valued at $624,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
HRTX stock traded up $0.44 during trading on Tuesday, reaching $26.61. The company had a trading volume of 751,488 shares, compared to its average volume of 987,484. Heron Therapeutics Inc has a 52 week low of $15.68 and a 52 week high of $29.49. The company has a market cap of $2.40 billion, a P/E ratio of -10.91 and a beta of 1.53. The business has a 50 day moving average of $21.55 and a 200 day moving average of $19.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.76 and a quick ratio of 3.51.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.15. The business had revenue of $42.62 million for the quarter, compared to analysts’ expectations of $34.02 million. Heron Therapeutics had a negative return on equity of 60.76% and a negative net margin of 140.55%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS. Research analysts expect that Heron Therapeutics Inc will post -2.44 earnings per share for the current year.
Several equities research analysts have weighed in on HRTX shares. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a report on Monday, August 5th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Friday, November 15th. Svb Leerink reissued an “outperform” rating on shares of Heron Therapeutics in a research note on Tuesday, November 12th. Cowen restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a report on Tuesday, October 1st. Finally, JMP Securities dropped their price target on Heron Therapeutics from $38.00 to $32.00 and set a “market outperform” rating for the company in a research note on Thursday, October 3rd. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $46.13.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: Price to Earnings Ratio (PE)
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.